Medicus Pharma Ltd (MDCX) Q3 2026 Earnings Report

The call was predominantly positive, driven by the Pfizer collaboration, access to a clinical-stage ADC with prior development experience, a focused melanoma strategy, the proposed $135 million SkinJect business combination, continued Teverelix partnering efforts and new financing. Offsetting factors included a higher nine-month net loss and operating expense base, increased liabilities, limited unrestricted cash, pending clinical and regulatory milestones, manufacturing issues for Teverelix and uncertainty around the nonbinding SkinJect transaction.

Medicus expects to concentrate incremental development investment on CD228V, initially in immunotherapy-resistant melanoma, with an objective response rate exceeding 30% as a development objective; it will advance SkinJect’s SKNJCT-005 study in parallel with the proposed business combination, targeting a $135 million pre-money enterprise valuation, concurrent equity financing, a projected estimate of approximately $3 million spread over the next 2 years, and completion during the first half of 2027, while management also described the budget as no more than $3 million spread over next 2 years; the company anticipates a substantial reduction in operating expenses in the coming quarters, expects FDA feedback on the Teverelix advanced prostate cancer program after approaching a 45-day mark, and said Teverelix product should become available sometime in the first quarter of next year.